s20098 has been researched along with Anxiety Neuroses in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Dimitrakopoulos, S; Konstantakopoulos, G; Michalopoulou, PG | 1 |
| Khoo, JP; Olivier, V; Picarel-Blanchot, F; Stein, DJ; Van Ameringen, M | 1 |
| Stein, DJ | 1 |
| Altamura, AC; Buoli, M; Grassi, S; Serati, M | 1 |
| Ahokas, A; Bauer, M; Bitter, I; de Bodinat, C; Hӧschl, C; Jarema, M; Khoo, JP; Matharan, S; Mosolov, SN; Olivier, V; Picarel-Blanchot, F; Stein, DJ; Van Ameringen, M; Vavrusova, L | 1 |
| Ilias, I; Karaiskos, D; Liappas, I; Paparrigopoulos, T; Tzavellas, E | 1 |
| De Berardis, D; di Giannantonio, M; Fornaro, M; Iasevoli, F; Marini, S; Martinotti, G; Perna, G; Quera-Salva, MA; Srinivasan, V; Tomasetti, C; Valchera, A | 1 |
| Ahokas, A; Albarran, C; Avedisova, AS; Höschl, C; Jarema, M; Márquez, MS; Oh, KS; Olivier, V; Stein, DJ | 1 |
| Altamura, AC; Buoli, M; Mauri, MC | 1 |
| Demyttenaere, K | 1 |
| Baldwin, DS; Elnazer, HY | 1 |
| Ahokas, A; Avedisova, AS; Chaban, O; de Bodinat, C; Gruget, C; Jarema, M; Olivier, V; Picarel-Blanchot, F; Stein, DJ; Vavrusova, L | 1 |
| Ahokas, AA; de Bodinat, C; Stein, DJ | 1 |
| Ahokas, A; de Bodinat, C; Fincham, D; Seedat, S; Stein, DJ | 1 |
| Kennedy, SH; Rizvi, SJ | 1 |
| Baldwin, DS; Lopes, AT | 1 |
| Chagas, MH; Crippa, JA; Hallak, JE; Nardi, AE; Quevedo, J; Zuardi, AW | 1 |
| David, DJ; Enhamre, E; Gabriel, C; Gardier, AM; Guilloux, JP; Hen, R; Mocaër, E; Rainer, Q; Xia, L | 1 |
| Ahokas, A; Albarran, C; Allgulander, C; Olivier, V; Stein, DJ | 1 |
| Acuña-Castroviejo, D; Lauterbach, EC; Othman, Z; Srinivasan, V; Zakaria, R | 1 |
| Levitan, MN; Nardi, AE; Papelbaum, M | 1 |
10 review(s) available for s20098 and Anxiety Neuroses
| Article | Year |
|---|---|
The preclinical discovery and development of agomelatine for the treatment of depression.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Circadian Rhythm; Depressive Disorder, Major; Drug Development; Drug Discovery; Humans | 2020 |
Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.
Topics: Acetamides; Anxiety; Anxiety Disorders; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine.
Topics: Acetamides; Anxiety Disorders; Humans; Quality of Life; Selective Serotonin Reuptake Inhibitors | 2021 |
Agomelatine for the treatment of generalized anxiety disorder.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Anxiety Disorders; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Product Surveillance, Postmarketing; Treatment Outcome | 2017 |
The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
Topics: Acetamides; Affect; Anxiety Disorders; Brain; Circadian Rhythm; Humans; Melatonin; Practice Patterns, Physicians' | 2013 |
Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder.
Topics: Acetamides; Anxiety Disorders; Humans; Hypnotics and Sedatives | 2014 |
Agomelatine in treating generalized anxiety disorder.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety Disorders; Double-Blind Method; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Sleep; Treatment Outcome | 2014 |
Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
Topics: Acetamides; Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2010 |
Agomelatine in depressive disorders: its novel mechanisms of action.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Disease Models, Animal; Humans; Melatonin; Receptors, Melatonin; Sleep Wake Disorders | 2012 |
A review of preliminary observations on agomelatine in the treatment of anxiety disorders.
Topics: Acetamides; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Humans; Randomized Controlled Trials as Topic | 2012 |
7 trial(s) available for s20098 and Anxiety Neuroses
| Article | Year |
|---|---|
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
Topics: Acetamides; Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Female; Follow-Up Studies; Humans; Interview, Psychological; Male; Middle Aged; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome; Young Adult | 2018 |
Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus.
Topics: Acetamides; Adolescent; Adult; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Middle Aged; Pilot Projects; Self Care; Sertraline; Treatment Outcome; Young Adult | 2013 |
Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
Topics: Acetamides; Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2014 |
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
Topics: Acetamides; Adult; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; International Cooperation; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Retrospective Studies; Treatment Outcome | 2017 |
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
Topics: Acetamides; Adolescent; Adult; Aged; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2008 |
The DSM-IV-based Generalized Anxiety Disorder Severity Scale: preliminary validation using data from a trial of agomelatine versus placebo.
Topics: Acetamides; Antidepressive Agents; Anxiety Disorders; Diagnostic and Statistical Manual of Mental Disorders; Humans; Hypnotics and Sedatives; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires | 2009 |
Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
Topics: Acetamides; Adult; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Female; Humans; Hypnotics and Sedatives; Kaplan-Meier Estimate; Male; Middle Aged; Personality Inventory; Psychometrics; Risk Factors; Secondary Prevention; Substance Withdrawal Syndrome | 2012 |
4 other study(ies) available for s20098 and Anxiety Neuroses
| Article | Year |
|---|---|
Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review.
Topics: Acetamides; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depression; Humans; Male; Selective Serotonin Reuptake Inhibitors; Semen Analysis; Spermatozoa | 2014 |
Agomelatine in the treatment of mood and anxiety disorders.
Topics: Acetamides; Antidepressive Agents; Anxiety Disorders; Humans; Hypnotics and Sedatives; Mood Disorders | 2010 |
Agomelatine in the treatment of social anxiety disorder.
Topics: Acetamides; Adult; Anxiety Disorders; Humans; Hypnotics and Sedatives; Male | 2010 |
Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Cell Proliferation; Circadian Rhythm; Corticosterone; Dendrites; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hippocampus; Male; Mice, Inbred C57BL; Motor Activity; Neurogenesis; Neurons; Serotonin 5-HT2 Receptor Antagonists | 2012 |